Urogen Pharma (NASDAQ:URGN) Insider Sells $2,854,852.85 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider owned 59,086 shares in the company, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Price Performance

NASDAQ URGN opened at $45.94 on Thursday. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $50.81. The stock’s 50-day moving average is $41.37 and its two-hundred day moving average is $29.68. The firm has a market cap of $2.25 billion, a P/E ratio of -23.20 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. On average, equities analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd acquired a new stake in shares of Urogen Pharma in the second quarter worth $66,000. Quantbot Technologies LP bought a new stake in Urogen Pharma in the 2nd quarter valued at $78,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares during the period. Russell Investments Group Ltd. grew its position in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on URGN shares. TD Cowen upped their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 price target on the stock. HC Wainwright boosted their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Finally, Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $50.38.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.